NANOPARTICLES LIPID CARRIERS CONTAINING RILUZOLE AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID PARTICLES (Brevetto)

Type

• Prodotto della ricerca (Classe)
• Brevetto (Classe)
• Brevetto (Classe)

Label

• NANOPARTICLES LIPID CARRIERS CONTAINING RILUZOLE AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID PARTICLES (Brevetto) (literal)

Anno

• 2008-01-01T00:00:00+01:00 (literal)

Alternative label

• M.L.BONDI', G. GIAMMONA,E.F. CRAPARO, F. DRAGO (2008)
  NANOPARTICLES LIPID CARRIERS CONTAINING RILUZOLE AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID PARTICLES
  
  (literal)

Titolo

• NANOPARTICLES LIPID CARRIERS CONTAINING RILUZOLE AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID PARTICLES (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• M.L.BONDI', G. GIAMMONA,E.F. CRAPARO, F. DRAGO (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#proprieta

• CNR/UNIPA/UNICT (literal)

Http://www.cnr.it/ontology/cnr/brevetti.owl#tipoDiBrevetto

• Internazionale (literal)

Numero brevetto

• WO 2008/000448 (literal)

Anno di deposito

• 2008 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• ISMN-CNR STEBICEF UNIPA DIPARTIMENTO DI FARMACOLOGIA SPERIMENTALE-UNICT (literal)

Titolo

• NANOPARTICLES LIPID CARRIERS CONTAINING RILUZOLE AND PHARMACEUTICAL FORMULATIONS CONTAINING SAID PARTICLES (literal)

Http://www.cnr.it/ontology/cnr/brevetti.owl#annoDiConcessione

• 2008 (literal)

Abstract

• The present invention relates to nanoparticulate lipid vectors containing riluzole, and the preparation and characterisation thereof. The systems obtained have a different biodistribution from the free drug in vivo, and can be used to prepare pharmaceutical formulations. STATE OF THE ART In view of their biodegradability and their ability to trap a variety of biologically active compounds, solid lipid nanoparticles are suitable for use as systems for modified drug release. For example, lipid nanoparticles have certain advantages over other colloidal vectors, such as the use of physiological lipids, the absence of organic solvents in the preparation process, a broad spectrum of applications, and the possibility of manufacture on a large scale at low cost. These systems are also able to modify the pharmacokinetics and biodistribution in vivo of the drugs trapped in them. Lipid nanoparticles can be used by various administration routes. Unfortunately, as these systems consist of pure lipids, some of them tend to crystallise, with the result that their drug loading is rather limited, and they tend to expel the drug with time. It is therefore necessary to develop materials based on lipids which are already used in the pharmaceutical field as excipients, but which do not crystallise when mixed together. Systems are thus obtained wherein the lipid matrix is amorphous, which means that larger amounts of the drug can be trapped, and it is more stable over time. (literal)

Prodotto di

• Istituto per lo studio dei materiali nanostrutturati (ISMN) (Istituto)
• Materiali e sistemi nanostrutturati per drug delivery e terapie medicali (PM.P05.004.010) (Modulo)

Autore CNR

• MARIA LUISA BONDI' (Unità di personale interno)

Incoming links:

Prodotto

• Istituto per lo studio dei materiali nanostrutturati (ISMN) (Istituto)
• Materiali e sistemi nanostrutturati per drug delivery e terapie medicali (PM.P05.004.010) (Modulo)

Autore CNR di

• MARIA LUISA BONDI' (Unità di personale interno)